辉瑞因潜在肝脏损伤停止减肥药测试Pfizer Ends Testing of Obesity Pill After Possible Liver Injury

动脉网

04-16

TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.2025年4月15日，星期二——辉瑞公司停止了一种每日一次的治疗...

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/news/2527425919"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527425919\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2527425919?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-04-16 01:35","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2527425919","market":"us","top_or_hot":-1,"title":"辉瑞因潜在肝脏损伤停止减肥药测试Pfizer Ends Testing of Obesity Pill After Possible Liver Injury","media":"动脉网","content":"<div>\n<p>TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.2025年4月15日，星期二——辉瑞公司停止了一种每日一次的治疗...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞因潜在肝脏损伤停止减肥药测试Pfizer Ends Testing of Obesity Pill After Possible Liver Injury</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞因潜在肝脏损伤停止减肥药测试Pfizer Ends Testing of Obesity Pill After Possible Liver Injury\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-16 01:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.2025年4月15日，星期二——辉瑞公司停止了一种每日一次的治疗...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b","article_id":"2527425919","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2527425919","pubTimestamp":1744738500,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Pfizer will now stop all testing of danuglipron, including its use with other drugs for obesity treatment. However, the company said it still plans to work on other obesity treatments that are in earlier stages of research.辉瑞将停止对丹纳格列波隆的所有测试，包括其与其他药物联合用于肥胖症治疗的测试。Even with recent price cuts, many of these medications still cost hundreds of dollars per month.即使近期价格有所下调，许多此类药物每月的费用仍高达数百美元。Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more than half the people in a trial stopped taking it.辉瑞公司已于 2023 年底停止了每日两次服用的丹那列普隆的测试，当时试验中超过一半的人已停止服用该药。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4534":"瑞士信贷持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999002232.USD":"Allianz Global High Payout USD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4588":"碎股","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","PFE":"辉瑞","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4581":"高盛持仓","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4592":"伊斯兰概念","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4599":"减肥药","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"Pfizer halts diet pill test over potential liver damage Pfizer Ends Testing of Obesity Pill After Possible Liver Injury","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.2025年4月15日，星期二——辉瑞公司停止了一种每日一次的治疗肥胖症药物的开发，因为一名临床试验参与者显示出可能的肝损伤迹象。The company said the injury went away after the person stopped taking the drug, called danuglipron,公司表示，该人士停止服用名为danuglipron的药物后，伤害消失了。The Associated Press美联社reported.已报告。The pill was in early testing to help determine the best dose, according to a Pfizer spokeswoman.据辉瑞公司发言人称，该药片正处于早期测试阶段，以帮助确定最佳剂量。The company had planned to move the drug into late-stage trials, typically the final step before review by the U.S. Food and Drug Administration (FDA).公司原计划将该药物投入后期试验，这通常是提交美国食品和药物管理局 (FDA) 审查前的最后一步。Pfizer will now stop all testing of danuglipron, including its use with other drugs for obesity treatment. However, the company said it still plans to work on other obesity treatments that are in earlier stages of research.辉瑞将停止对丹纳格列波隆的所有测试，包括其与其他药物联合用于肥胖症治疗的测试。然而，该公司表示仍计划继续研究其他处于早期阶段的肥胖症治疗方法。Obesity drugs have become a major focus for pharmaceutical companies. Injectable treatments like Eli Lilly’s肥胖症药物已经成为制药公司的主要关注点。像礼来公司（Eli Lilly）的可注射治疗药物等。Zepbound泽普绑定and Novo Nordisk’s诺和诺德的Wegovy韦哥维have brought in billions in revenue. Zepbound earned nearly $5 billion in 2024 alone,带来了数十亿美元的收入。仅2024年，Zepbound就赚了近50亿美元，The Associated Press美联社reported.据报道。But these drugs must be injected, which some folks don't want to do.但是这些药物必须通过注射，有些人不想这样做。As a result, drugmakers have been racing to develop pill versions. Lilly expects to release new data this year on two oral obesity drugs it is studying.因此，制药商一直在竞相开发药片版本。礼来公司预计将在今年发布其正在研究的两种口服减肥药的新数据。While demand for these treatments is high, access has been an issue. Some patients face insurance issues or high out-of-pocket costs.虽然对这些治疗的需求很高，但获取途径一直是个问题。一些患者面临保险问题或高昂的自付费用。Even with recent price cuts, many of these medications still cost hundreds of dollars per month.即使近期价格有所下调，许多此类药物每月的费用仍高达数百美元。Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more than half the people in a trial stopped taking it.辉瑞公司已于 2023 年底停止了每日两次服用的丹那列普隆的测试，当时试验中超过一半的人已停止服用该药。Whatever your topic of interest,无论你感兴趣的话题是什么，subscribe to our newsletters订阅我们的新闻通讯to get the best of Drugs.com in your inbox.获取 Drugs.com 的最新资讯到您的邮箱。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}